Abstract:Abstract Background Patients with Mycosis Fungoides (MF)/Sézary Syndrome (SS) can experience impacted health-related quality of life (HRQoL). Objectives To validate the CTCL-S, a novel subscale of the Functional Assessment of Cancer Therapy – General (FACT-G), in patients with MF/SS. Methods Qualitative interviews were conducted with expert clinicians and MF/SS patients. Thematic analysis identified the most common concerns, and 19 items were selected. MF/SS patients were recruited from a single center. FACT-G, CTCL-S (collectively “FACT-CTCL”), Skindex29, and Visual Analogue Scale–Pruritis (VAS itch) were administered. A subset repeated FACT-CTCL and VAS itch after ≈2 weeks. Patient demographics and clinical characteristics were obtained via review of the electronic medical record. Psychometric properties were assessed. Internal consistency was estimated using Cronbach’s alpha (α). Convergent and discriminant validity were assessed by comparing CTCL-S to disease stage, age, VAS itch, FACT-G, and SkinDex29. Exploratory factor analysis (EFA) was used to preliminarily assess CTCL-S dimensionality. Test-retest repeatability was summarized using intraclass correlation coefficient (ICC), within-subject standard deviation (wSD), and within-subject coefficient of variation. Results Seventy-two patients completed the initial survey, and 35 repeated the FACT-CTCL and VAS itch after ≈2 weeks. Two-thirds were male, most were white (78%). The majority (85%) had MF, 15% SS, and 75% early (stage IA-IIA) and 25% advanced (≥ stage IIB) disease. Preliminary EFA found a single predominant factor, supporting a hypothesis of unidimensionality of the CTCL-S. Internal consistency of the CTCL-S was high (α: 0.95 [95% CI: 0.93-0.96]). There was no significant change in CTCL-S average test-retest scores (ICC of 0.93 (p = 0.63)). CTCL-S was significantly lower in advanced vs early stage disease (median[IQR]: 34[26, 48] vs. 59[44, 68], p < 0.001) and strongly correlated with VAS itch (Spearman’s r (rs): -0.70, 95% CI: -0.81, -0.55), FACT-G (rs: 0.77, 95% CI: 0.65, 0.85), and Skindex29 (rs: -0.90, 95% CI: -0.94, -0.84), supporting convergent validity. CTCL-S scores had little correlation with age (rs: 0.19, 95% CI: -0.05, 0.41, p = 0.12), supporting discriminant validity. Conclusions The FACT-CTCL is a disease specific instrument for assessing HRQoL with high reproducibility and good performance in a cohort of patients with MF/SS.

Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma

Health-related quality of life among women with ductal carcinoma in situ or early invasive breast cancer: validation of the FACT-B (version 4)

The Efficacy Of A New High-Intensity Focused Ultrasound Therapy For Metastatic Pancreatic Cancer

Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy–Thrombocytopenia (FACT-Th) questionnaire

Baseline Radiologic Features As Predictors of Efficacy in Patients with Pancreatic Neuroendocrine Tumors with Liver Metastases Receiving Surufatinib.

Development and psychometric properties of the Functional Assessment of Cancer Therapy-Cutaneous T-Cell Lymphoma (FACT-CTCL)

Assessing the reliability of a novel cancer-specific multi-attribute utility instrument (FACT-8D) and comparing its validity to EQ-5D-5L in colorectal cancer patients

Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer

Psychometric Properties of the Functional Assessment of Cancer Therapy-General for Evaluating Quality of Life in Patients With Life-Limiting Illness in the Emergency Department

Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B

Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients

Development of the Functional Assessment of Cancer Therapy–Immune Checkpoint Modulator (FACT‐ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs

Psychometric Properties of the Chinese Version of the Functional Assessment of Cancer Therapy-Cervix (Fact-Cx) Measuring Health-Related Quality of Life

Reliability and validity of a novel cognitive self-assessment tool for patients with cancer

Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

The EORTC QLQ breast modules and the FACT-B for assessing quality of life in breast cancer patients - an updated literature review

Comparing the EORTC QLQ-LC13, EORTC QLQ-LC29, and the FACT-L for assessment of quality of life in patients with lung cancer - an updated systematic review

The Metastasis Status and Tumor Burden-Associated CA125 Level Combined with the CD4/CD8 Ratio Predicts the Prognosis of Patients with Advanced Pancreatic Cancer: A New Scoring System

Hand-Foot Syndrome (hfs) and Asthenia/Fatigue (A/F) As Biomarkers of Sunitinib Efficacy in Chinese Patients (pts) with Metastatic Renal Cell Carcinoma (Mrcc).